Six Flags Inc. Outlook Revised to Negative On Weak Second-Quarter Operating Performance Aug 02

  • ID: 1831841
  • August 2002
  • Standard & Poors
1 of 3

NEW YORK (Standard & Poor's) Aug. 15, 2002--Standard & Poor's Ratings Services said today that it has revised its outlook on theme park operator Six Flags Inc. to negative from stable based on weak second-quarter operating performance and management's revision of full-year EBITDA guidance. Standard & Poor's said that its ratings, including its double-'B'-minus corporate credit rating on company were affirmed. Six Flags, based in Oklahoma City, Okla. is the largest regional theme park operator and the second-largest theme park company in the world. The company operates 38 parks, with 28 in the U.S., eight in Europe, one in Canada and one in Mexico. Total debt and preferred stock as of June 30, 2002, was $2.6 billion. "EBITDA declined 10%...

Companies mentioned in this report are:
- Six Flags Entertainment Corp.

Action: Outlook Revised

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

- Six Flags Entertainment Corp.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.